NAACCR CERTIFICATION AND THE CINA DATA SUBMISSION

FCDS 2023 VIRTUAL ANNUAL CONFERENCE: SESSION 3

RECINDA SHERMAN, PROGRAM MANAGER OF DATA USE & RESEARCH, NAACCR

PRESENTATION OVERVIEW

- NAACCR Call for Data
 - Define processes that central registries are expected to perform
 - Death Clearance, Deduplication, Geocoding
 - Define process for evaluation
 - NAACCR Certification, CiNA Evaluation
 - Completeness, Quality, Timeliness
- How Florida data are used in CiNA



WHAT IS NAACCR?

- NAACCR pronounced "Nay-Sir"
 - North American Association of Central Cancer Registries
 - US and CAN (yeah, Mexico is North American but ☺)
- Standard setter (but not a funder)
- Umbrella organization
 - Infrastructure for collaboration and support of central cancer registries and cancer surveillance – greatest strength is our members

NAACCR CALL FOR DATA (CFD) OVERVIEW

- Focus on NAACCR CFD https://www.naaccr.org/call-for-data/
 - Florida also participates in NPCR/CDC CFD
 - Coordinated but separate submissions
- NAACCR CFD
 - Primary Goal NAACCR Certification (Single year, 2021)
 - Secondary Goal CiNA statistics (Multiple years, 1995-2021)
 - Cancer in North America (CiNA)
 - Produce US, Canada, and State-specific statistics
 - Incidence, survival, prevalence, trends, Annual Report to Nation, ACS F&F, delayed rates
 - Tertiary Goal National-level research
 - Support NAACCR approved research (internal and external researchers)



NAACCR CALL FOR DATA (CFD) VS NCDB


- Some aspects are similar to the ACS/NCDB CFD
 - Annual (Nov/Dec vs Mar), submission portal, NAACCR layout,
 .xml, 24 months
 - Set case selection criteria, select variables
 - Case Ascertainment/Completeness is evaluated
 - "frantic search for cases" multiple reporting sources
 - Edits—100% resolution



- Prior to creation of submission file
 - Case ascertainment
 - Death Clearance
 - Physician office reporting unique effort by Florida
 - Deduplication
 - Updated protocol
 - Match*Pro Florida was directly involved in development
 - Geocoding
 - Patient address



Proportion of Unknown Race by Leukemia & Myeloma cases





- Death Clearance
 - NAACCR Certification Criteria
 - One of many efforts toward complete case ascertainment
 - Minimum requirements updated 2023 https://www.naaccr.org/wp-content/uploads/2023/05/NAACCR Death-Clearance Manual-4-23-FINAL.pdf
- Link database to mortality records
 - Append death information (date, cause) to cancer record
 - Identify missed cases
- Follow-back to hospitals and physicians to move "DCO" to higher quality case, more complete information



- Deduplication
 - NAACCR Certification Criteria
 - Patient-level
 - Protocol updated last year—significant effort
 - 100% resolution all years of data (1995-2021)
 - Tumor-level
 - Protocol update this year—significant effort
 - Role out to manage the burden
 - 5 years deduplicated to meet the Criteria (Gold)
 - Next year 15 years will be deduplicated



- Geocoding
 - Now on-going process; geocoder incorporated (API) into FCDS system
 - historically annual, manual effort (extract, upload, process, download, reimport)
 - "spatially enable" cancer data geocoding based on patient address at diagnosis
 - Quality of incoming address data greatly influences geocoding burden
- Geocoded data
 - NAACCR Certification Criteria (County at Diagnosis—Analysis, derived field, NAACCR Item #89)
 - Supports county-level surveillance, cancer cluster investigations, small area research, hospital catchment area analysis, health equity research, health disparities research, geospatial epidemiology

NAACCR CALL FOR DATA (CFD) SUBMISSION FILE

- Create submission file
 - Cases consolidated from all reporting sources
- Run and resolve edits
 - Regular edits AND inter-record edits
- Create output file using the tool NAACCR PREP
 - Creates packaged .xml submission file
 - Derives calculated fields (e.g., survival variables, NAACCR poverty code)
 - Deletes PHI and non-required variables
- Submit file
 - 24 month for Certification, 12 month for evaluation, 1995+ for research



NAACCR CALL FOR DATA (CFD) POST-SUBMISSION

- Submission Forms & Signed Documents
 - Details on submission counts, processes, etc
 - Data Assurance Agreement
 - Consent for On-going CiNA Research
 - ACS Facts & Figures, MTC postmarket surveillance (FDA requirement), CiNA Public Use Dataset, American Lung Association Annual Report, Delay Adjustment Modeling, Impact of Affordable Care Act on Cancer Stage at Diagnosis
- CaRI Cancer Researcher Information DB
- Special projects submissions (VPR, NCCR)



NAACCR CERTIFICATION

- https://www.naaccr.org/certification-criteria/
- Completeness meets NAACCR Completeness Criteria
- Quality meet 5 criteria
 - % DCO, % unknown county, % unknown age, % unknown race, 100% edit free, duplicates
- Timeliness submission by December deadline
 - 23 months from close of diagnosis year
- Update—NAACCR Board Priority, changes may be coming







NAACCR COMPLETENESS

- NAACCR Completeness Estimate
 - Summary statistic
 - Florida Incidence to Mortality Ratio compared to Nationa Incidence (SEER) to Mortality (US) ratio
- Additional Measures to improve on method
 - Internal and external
 - Completeness Metrics



NAACCR COMPLETENESS CALCULATION

Worksheet for Completeness of Case Ascertainment, version 2.2.b													
Registry Incidence and Mortality Rates, by race/by sex (this example showing male sites)													
		Registry		SEER (11 Regs) and US Mortality			Unadjusted Results		Mortality Adjustment Terms		t Terms	Adjusted for Mortality	
by race, by sex	Age-Adjusted Rates (2000 US)			Age-Adjusted Rates (2000 US)			Expected	Unadjusted	Registry		Adj Reg	Expected	Interim
	2020	2019-2020	Inc/Mort	2016-2020	2016-2020	Inc/Mort	Incidence	Percent	2016-2020	Adjust.	2019-2020	Incidence	Percent
Cancer Site	Incidence	Mortality	Ratio	Incidence	Mortality	Ratio	Rate	Complete	Mort Rate	Term	Mort Rate	Rate	Complete
Oral Cavity and Pharynx			0.00	12.25	4.25	2.88	-	0.0		1.0000	-	-	- 0.0
Esophagus			0.00	4.54	4.84	0.94	-	0.0		1.0000	-	-	- 0.0
Stomach			0.00	11.76	7.29	1.61	-	0.0		1.0000	-	-	0.0
Colon and Rectum			0.00	46.21	22.06	2.10	-	0.0		1.0000	-	-	- 0.0
Liver			0.00	15.73	11.00	1.43	-	0.0		1.0000	-	-	0.0
Pancreas			0.00	15.96	14.92	1.07	-	0.0		1.0000	-	-	0.0
Lung and Bronchus			0.00	62.08	52.38	1.19	-	0.0		1.0000	-	-	- 0.0
Melanomas of the Skin*			0.00	1.26	0.38	3.32	-	0.0		1.0000	-	-	- 0.0
Prostate*			0.00	167.47	36.99	4.53	-	0.0		1.0000	-	-	- 0.0
Bladder (including in situ)			0.00	19.65	5.21	3.77	-	0.0		1.0000	-	-	0.0
Kidney and Renal Pelvis			0.00	25.29	5.09	4.96	-	0.0		1.0000	-	-	0.0
Brain and Other Nervous System			0.00	4.57	3.22	1.42	-	0.0		1.0000	-	-	- 0.0
Hodgkin Lymphoma			0.00	2.88	0.31	9.34	-	0.0		1.0000	-	-	0.0
Non-Hodgkin Lymphoma			0.00	17.67	5.04	3.50	-	0.0		1.0000	-	-	0.0
Multiple Myeloma			0.00	15.98	7.23	2.21	-	0.0		1.0000	-	_	0.0
Leukemias			0.00	13.41	6.61	2.03	-	0.0		1.0000	-	-	0.0
Sum of Rates by race, by sex	-						-	0.0				-	0.0


https://www.naaccr.org/analysis-and-data-improvement-tools/#1682337822557-



2020 COMPLETENESS ESTIMATES

- Standard NAACCR Completeness Method was not appropriate to evaluate case completeness for the 2020 data
 - Change in medical care access resulted in decrease of diagnosis
 - Change does NOT reflect decrease in burden of cancer
 - Exclude 2020 in trend analysis
- Evaluated 2020 submission data & developed/applied adjustment
 - Goal 1: apply an adjustment that does not penalize registries for decreased # of cancer cases diagnosed due to changes in medical access
 - Goal 2: do not adjust away operational issues (due to covid or other factors) that resulted in decreased # of cancer cases collected
 - https://narrative.naaccr.org/article/winter-2023-research-data-use-update/
- Will evaluate 2021 submission data
 - Adjustment will be applied if necessary





NAACCR CERTIFIED REGISTRIES FOR 2022 (BASED ON DIAGNOSIS YEAR 2020)

ADDITIONAL EVALUATIONS

- Additional Recognitions:
 - Fit for Use: Survival/Prevalence



- More coming......
- Data Assessments and Evaluation
 - Most recent 5 years of data for inclusion in CiNA
 - NAACCR Committee Work -- quality assessments & eval
 - Data Profiles https://www.naaccr.org/data-quality-assessments-and-evaluations/
 - Project specific evaluation
- Data Visualizations





NAACCR REGISTRIES
RECOGNIZED FIT FOR USE
FOR
SURVIVAL/PREVALENCE
FOR 2022
(BASED ON DIAGNOSIS
YEARS 2008-2019)

DATA ASSESSMENT VISUALIZATIONS

- Demo Certification Criteria
 - DCO, Race
- Demo additional Completeness Metrics
 - % Non-Malignant Brain, % DCOs, % Leukemia & Myeloma, %
 Ill defined site, % Microscopically confirmed
- Demo CiNA Evaluation
 - Inclusion criteria, key data fields (unknown race)



CANCER IN NORTH AMERICA DATA PRODUCTS (CINA)

- Top 5 Cancers
 - https://www.naaccr.org/top-5-cancers/
- Interactive Statistics
 - NAACCR Cancer Maps (demo oral cancer data)
 - https://www.cancer-rates.info/naaccr/
 - CiNA*Explorer (demo Florida vs US by race/ethnicity, HPV-associated)
 - https://apps.naaccr.org/explorer/
- CiNA Research Datasets (released in SEER*Stat)
 - CiNA Public Use Dataset annual permission to use Florida data
 - https://www.naaccr.org/cina-public-use-data-set/
 - CiNA Research Files project-specific to use Florida data
 - https://www.naaccr.org/cina-data-products-overview/
 - Data requested through DaRT: https://apps.naaccr.org/dart/
 - Requires a free, MyNAACCR account to log-in



"MAKE EVERY CANCER COUNT"

Foundational data abstracted by hospital CTRs and registrars

Central registry staff process, clean, standardize and augment from other sources

Population-based

NAACCR processes, cleans, standardizes, and augments

National dataset

Produce essential statistics to support cancer planning and control

Make relevant research datasets available to support public health research

Goal = reduce the burden of cancer



QUESTIONS?

Contact:

Recinda Sherman

rsherman@naaccr.org

